Industry Cost Structure Must Change, But Will Not Start At AstraZeneca – CEO

AstraZeneca CEO Tom McKillop called on the pharmaceutical industry to reduce the costs associated with selling and marketing drugs, but does not believe his company will be the catalyst for change